Morgan Stanley’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Morgan Stanley’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-58,904	Closed	-$156K	–	6883
2020 Q1	$156K	Sell	58,904 -14,550	-20%	-$23.9K	﹤0.01%	4980
2019 Q4	$86K	Buy	73,454 +540	+0.7%	+$863	﹤0.01%	5699
2019 Q3	$126K	Buy	72,914 +32,392	+80%	+$98.6K	﹤0.01%	5359
2019 Q2	$192K	Buy	40,522 +3,939	+11%	+$22.1K	﹤0.01%	5045
2019 Q1	$236K	Sell	36,583 -12,479	-25%	-$65.3K	﹤0.01%	4972
2018 Q4	$247K	Buy	49,062 +34,659	+241%	+$243K	﹤0.01%	5195
2018 Q3	$123K	Buy	14,403 +11,099	+336%	+$123K	﹤0.01%	5628
2018 Q2	$42K	Buy	+3,304	New	+$45.2K	﹤0.01%	5953

Morgan Stanley's NTGN Position: Q2 2020 in Review

Morgan Stanley sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 58,904 shares — an estimated $156K sold.

Morgan Stanley first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $247K in Q4 2018. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Morgan Stanley reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Morgan Stanley sold 58,904 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $156K.
Morgan Stanley first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Morgan Stanley's Neon Therapeutics, Inc. Common Stock position peaked at $247K in Q4 2018.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Morgan Stanley's 13F filing for Q2 2020, filed 14 Aug 2020.